The company had a challenging fiscal first quarter due to the deletion of CPT codes that payors used to use to reimburse hereditary cancer testing.
The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.
In a letter to CMS, AMP made a case for crosswalking existing CPT codes for BRCA1/2 testing to codes that more accurately reflect the work required to analyze these genes.
The firm has struggled in the past to convince payors of its test's clinical utility but remains dedicated to convincing the field that Epi proColon can help patients by closing CRC screening gaps.
Since last year the AMA has issued 23 PLA codes for firms that want to better track use of their tests, but the effect of the codes on improving reimbursement remains to be seen.
The panel's decisions could change the codes diagnostic companies use to bill payors for these tests, which could affect revenue.
The new code is used for tests conducted by next-generation sequencing that include BRCA1, BRCA2, and 12 other genes even if they are part of multi-gene panels.
The coding requirements will be a particularly complicated aspect of implementing the new law which aims to move diagnostic pricing to a market-based system.
Medicare Administrative Contractors didn't price codes describing whole-genome or exome sequencing, or cancer panels gauging 51 or more genes.
NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services has released its preliminary clinical laboratory fee schedule (CLFS) deter
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.